Comments on the 2021 ESC guidelines on cardiovascular disease prevention in clinical practice

  1. Arrarte, Vicente 1
  2. Alarcón Duque, José Antonio 1
  3. Aldama, Guillermo 1
  4. Barrios, Vivencio 1
  5. Bonanad, Clara 1
  6. Castro Conde, Almudena 1
  7. Fernández Olmo, Rosa 1
  8. Gámez, José M. 1
  9. Guzmán-Martínez, Gabriela 1
  10. Neiro Rey, Carmen 1
  11. Vivas, David 1
  12. Avanzas, Pablo 1
  13. Berga Congost, Gemma 1
  14. Boraita, Araceli 1
  15. Bueno, Héctor 1
  16. Calvo, David 1
  17. Campuzano, Raquel 1
  18. Delgado, Victoria 1
  19. Dos, Laura 1
  20. Ferreira-Gonzalez, Ignacio 1
  21. Gomez Doblas, Juan José 1
  22. Pascual Figal, Domingo 1
  23. Sambola, Antonia 1
  24. Viana Tejedor, Ana 1
  25. Ferreiro, José Luis 1
  26. Alfonso, Fernando 1
  27. Mostra tots els autors/es +
  1. 1 SEC Working Group for the 2021 ESC guidelines on cardiovascular disease prevention in clinical practice and SEC Guidelines Committee
Revista:
Revista Española de Cardiología (English Edition)

ISSN: 1885-5857

Any de publicació: 2022

Volum: 75

Número: 5

Pàgines: 364-369

Tipus: Article

DOI: 10.1016/J.REC.2021.10.023 GOOGLE SCHOLAR lock_openAccés obert editor

Altres publicacions en: Revista Española de Cardiología (English Edition)

Resum

The present article summarizes the main novelties in the recently published cardiovascular disease prevention guidelines of the European Society of Cardiology (ESC),1 comparing them with the previous recommendations2 and examining both their positive aspects and those that may be controversial. In addition, we comment on their applicability to routine clinical practice, taking into account the socioeconomic characteristics of Spain. We do not seek to contradict the recommendations, drafted by

Referències bibliogràfiques

  • Visseren, (2021), Eur Heart J., 42, pp. 3227, 10.1093/eurheartj/ehab484
  • Piepoli, (2016), Eur Heart J., 37, pp. 2315, 10.1093/eurheartj/ehw106
  • Mach, (2020), Eur Heart J., 41, pp. 111, 10.1093/eurheartj/ehz455
  • Valgimigli, (2018), Eur Heart J., 39, pp. 213, 10.1093/eurheartj/ehx419
  • Williams, (2018), Eur Heart J., 39, pp. 3021, 10.1093/eurheartj/ehy339
  • Barrios, (2021), Rev Esp Cardiol., 74, pp. 827, 10.1016/j.recesp.2021.04.015
  • Quesada, (2021), Rev Esp Cardiol., 10.1016/j.recesp.2021.08.008
  • Hindricks, (2021), Eur Heart J., 42, pp. 373, 10.1093/eurheartj/ehaa612
  • Campuzano, (2021), REC: CardioClinics., 56Supl1, pp. 27
  • Zelniker, (2019), Lancet., 393, pp. 31, 10.1016/S0140-6736(18)32590-X
  • Kristensen, (2019), Lancet Diabetes Endocrinol., 7, pp. 776785, 10.1016/S2213-8587(19)30249-9
  • Neal, (2021), N Engl J Med., 10.1056/NEJMoa2105675
  • Koo, (2021), Lancet., 397, pp. 2487, 10.1016/S0140-6736(21)01063-1
  • Knuuti, (2020), Eur Heart J., 41, pp. 407, 10.1093/eurheartj/ehz425
  • ASCEND Study Collaborative Group, Bowman L, Mafham M, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379:1529-1539.
  • Dunlay, (2016), Curr Cardiovasc Risk Rep., 10, pp. 3, 10.1007/s12170-016-0491-8
  • Forman, (2018), J Am Coll Cardiol., 71, pp. 2149, 10.1016/j.jacc.2018.03.022
  • Rahimi, (2018), PLoS Med., 15, pp. e1002545, 10.1371/journal.pmed.1002545
  • Salzwedel, (2020), Eur J Prev Cardiol., 27, pp. 1756, 10.1177/2047487320905719
  • Long, (2019), Cochrane Database Syst Rev., 1, pp. CD003331